
Let us advance cancer therapies together
Join us at AACR 2025 to explore how Champions Oncology’s in vivo, ex vivo platforms, and clinical specialty testing services can fast-track your cancer drug development.
Champions' team of expert scientists are presenting 16 novel research posters at the 2025 annual meeting. Discover how our innovative oncology services portfolio can support your research and upcoming clinical trials. To plan your meeting, you can download and save each poster's schedule to your calendar. The posters will be available for download after the conference.
Sunday - April 27, 2025
Monday - April 28, 2025
Tuesday - April 29, 2025
Wednesday - April 30, 2025
Book a Meeting with Leading Experts
Meet Dr. Shankar Vallabhajosula, a recognized leader in Radiochemistry and Radiopharmacy, and Dr. Steffi Oesterreich, an expert in Breast Cancer research, at our booth. Engage with these key opinion leaders and the Champions team to explore strategies and solutions for your cancer drug development project. Contact us today to book a meeting.

Dr. Steffi Oesterreich is a leading expert in breast cancer research, with a particular focus on invasive lobular carcinoma (ILC), a common yet understudied breast cancer subtype. Her work aims to advance the understanding of breast cancer development and progression to improve patient outcomes. Using genetic and epigenetic analyses, cell line and animal models, and clinical samples, her research explores the mechanisms driving disease progression. Currently, her team is investigating estrogen receptor (ER) mutations, which occur in 20-40% of metastatic ILC cases, to develop targeted therapeutic strategies for overcoming resistance and improving endocrine therapy efficacy.

Dr. Shankar Vallabhajosula is a distinguished expert in radiochemistry and radiopharmacy with over four decades of experience in nuclear medicine. He earned his Ph.D. from the University of Southern California and has held academic positions at Mount Sinai Medical Center and Weill Cornell Medicine, where he is now Professor Emeritus. Dr. Vallabhajosula has authored over 130 publications and played a key role in developing more than 30 investigational radiopharmaceuticals, including [18F]FDG. A recipient of multiple awards, he continues to advance radiopharmaceutical sciences in both academic and industry settings.